Utility of ¹⁸F-fluoroestradiol (¹⁸F-FES) PET/CT imaging as a pharmacodynamic marker in patients with refractory estrogen receptor-positive solid tumors receiving Z-endoxifen therapy

详细信息    查看全文

• 作者：Frank I. Lin ; E. M. Gonzalez ; S. Kummar…
• 关键词：18F ; FES ; Fluoroestradiol ; Positron emission tomography (PET) ; Z ; endoxifen ; Pharmacodynamic marker
• 刊名：European Journal of Nuclear Medicine and Molecular Imaging
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：44
• 期：3
• 页码：500-508
• 全文大小：
• 刊物类别：Medicine
• 刊物主题：Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology;
• 出版者：Springer Berlin Heidelberg
• ISSN：1619-7089
• 卷排序：44

文摘

BackgroundZ-endoxifen is the most potent of the metabolites of tamoxifen, and has the potential to be more effective than tamoxifen because it bypasses potential drug resistance mechanisms attributable to patient variability in the expression of the hepatic microsomal enzyme CYP2D6. 18F-FES is a positron emission tomography (PET) imaging agent which selectively binds to estrogen receptor alpha (ER-α) and has been used for non-invasive in vivo assessment of ER activity in tumors. This study utilizes 18F-FES PET imaging as a pharmacodynamic biomarker in patients with ER+ tumors treated with Z-endoxifen.